Clinical Trials - December 17, 2025
Zelluna publishes new preclinical data
Zelluna has announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances.
Biotech Business - December 17, 2025
Cellevate achieves ISO 9001:2015 certification
This marks a major milestone for Cellevate to becoming an industrial bioprocessing supplier, states the company.
MedTech Business - December 17, 2025
Vitrolife announces genetic services restructuring program
The program is targeting annualised savings of SEK 65 million, expected to have a positive impact in the first half of 2026, and to reach full effect by the end of the third quarter 2026.
Clinical Trials - December 16, 2025
Affibody accelerates Phase 1 study
The Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer to its second part, where higher radioactivity levels will be evaluated.
Biotech Business - December 15, 2025
Hansa Biopharma reorganizes
Hansa Biopharma has announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025.
In a new job - December 15, 2025
ALK appoints EVP & Head of Commercial Operations North America
Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy.
